DOI: http://dx.doi.org/10.18203/2349-2902.isj20205425

Effectiveness of tolterodine in relief of postoperative symptoms related to urethral catheter in transurethral prostate resection patients: a prospective randomized trial

Faraj Afandiyev, Mehmet Ilker Gökçe, Cihat Özcan, Anar İbrahimov, Ömer Gülpinar

Abstract


Background: Urethral catheterisation following surgery causes significant discomfort postoperatively. Use of muscarinic receptor antagonists for relief of these symptoms in transurethral prostate resection (TURP) patients has been studied previously. In this study it is aimed to identify efficacy of toltoredine for relief of bladder overactivity symptoms in the post-operative period following TURP.

Methods: In this randomized, prospective, controlled study, results of 95 patients evaluated. Group 1(n=49) received tolterodine 4 mg/day and group 2 (n=45) received no medication. Presence and severity of symptoms together with visual pain scale (VPS) scores were recorded and compared in very early and late postoperative period (0, 4, 8, 12, 24 hours and every 24 hours thereafter). Additional analgesic requirement was also compared and adverse events were recorded.

Results: Tolerodine treatment was shown to be associated with low incidence and less severity of symptoms. Symptoms were shown to be present especially in the early postoperative period. VPS scores were also shown to be less in group 1. Treatment was not cessated in any of the patients due to adverse events.  

Conclusions: Tolterodine 4 mg/day was shown to be effective in relief of symptoms related to urethral catheterisation in the postoperative period following TURP. Treatment was not cessated in any of the patients due to adverse events. Further prospective placebo-controlled studies are needed with tolterodine and other muscarinic receptor antagonists.


Keywords


Bladder overactivity, Muscarinic receptor antagonists, Tolterodine, Transurethral resection of prostate

Full Text:

PDF

References


Andersson KE. Advances in the pharmacological control of the bladder. Exp Physiol. 1999;84:195-213.

Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004:3:46-53.

Agarwal A, Dhiraaj S, Singhal V, Kapoor R, Tandon M. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Br J Anaesth. 2006;96(3):377-80.

Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007:100:987-1006.

Aschkenzai S, Botros S, Miller J, Gamble TP, Goldberg R. Overactive bladder symptoms are not related to detrusor overactivity. Neurourol Urodyn. 2007:26:35.

Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003:22:105-8.

Agarwal A, Raza M, Singhal V. The efficacy of tolterodine for prevention of catheter-related bladder discomfort: a prospective, randomized, placebocontrolled, double-blind study. Anesth Analg. 2005;101(4):1065-7.